Clinical utility of Gallium 68 Prostate Specific Membrane Antigen (68Ga-PSMA) Positron Emission Tomography (PET) imaging in patients with initial biochemical relapse following definitive surgery or radiotherapy for prostate carcinoma (PCa), to determine the sensitivity of 68Ga-PSMA imaging in the detection of PCa and using intention to treat analysis to assess change in management.
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2016
At a glance
- Drugs Gallium 68 PSMA (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 18 Jun 2015 New trial record